The Company's goal is to become a strong alliance partner for pharmaceutical and biopharmaceutical companies prior to the initiation of IND activities.
CT Atlantic does not intend to become a fully integrated pharmaceutical company by building regulatory and clinical development capacities. Rather, it aims to focus its activities on the generation of a pipeline of preclinical assets that can be transferred at an early stage to a pharma partner who can control the development of such products - potentially with the support of CT Atlantic’s clinical network.
Key Collaborations:
University of Zurich
Krankenhaus Nordwest
Ludwig Institute for Cancer Research
Commercial Partners
HS LifeSciences AG
Investors:
QureInvest AG